Abstract: Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.

Abstract: Injection of particulate materials into industrial processes can be improved through use of a vessel mounted on a weighing device and which is vented through use of two separate and distinct valves. Optionally, a predetermined pressure in the vessel is maintained through use of a pressure transmitter and an on/off mode of operation.

Abstract: Bimodal amporphous inorganic material that in a pore size distribution plot has distinct mesopore and micropore peaks. A process for producing a bimodal material or a material that contains essentially only mesopores involves heating an inorganic oxide in the presence of material that bonds to the inorganic oxide by hydrogen bonding.

Abstract: The present invention relates to the use of pharmaceutically acceptable cholinesterase inhibitors for the preparation of a pharmaceutical composition for the treatment or prophylaxis of arthritic disorders, including osteoarthritis, rheumatoid arthritis and other rheumatoid diseases such as Juvenile Arthritis, Systemic Lupus Erythematosis, Sjogren's Syndrome, Progressive Systemic Sclerosis, Polymyositis, Dermatomyositis, Ankylosing Spondilitis, Reiter's Syndrome, Psoriatic Arthritis, Relapsing Polychondritis, Relapsing Panniculitis, Crohn's Disease, Ulcerative Colitis, Heredity Complement Deficiencies, Collagen Vascular Diseases, Felty's Syndrome, rheumatological manifestations associated with bacterial and viral endocarditis or myocarditis and other rheumatological manifestations such as anaemia of chronic disorders. The invention also relates to a novel method of treatment or prophylaxis of such diseases and manifestations.

Abstract: This invention relates to the synthesis of large pore composite molecular sieves and to the synthetic large pore composite molecular sieves so produced. The molecular sieves of the invention have the same general utilities of the comparable molecular sieves of the prior art but have been found to be superior catalysts and absorbents. This invention relates to a hydrothermal synthesis of large pore molecular sieves from nutrients, at least one of which contains an amorphous framework-structure, and which framework-structure is essentially retained in the synthetic molecular sieve. This invention stems from a discovery that the intrinsic porosity characteristics of a nutrient that possesses an amorphous cation oxide-framework can be substantially retained in the final molecular sieve containing product formed by a hydrothermal process by carefully controlling the conditions under which the hydrothermal process is conducted.

Abstract: A composition which comprises human mesenchymal stem cells which have the potential to differentiate into cells of more than one connective tissue type and a composition which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage, and a process for inducing such differentiation. The composition for inducing such differentiation comprises a glucocorticoid, a compound which stimulates cAMP production or inhibits cAMP degradation (such as a phosphodiesterase inhibitor), and/or a compound which upregulates peroxisome proliferator activated receptor &ggr; (PPAR &ggr;) expression and/or increases its binding affinity to its DNA binding site. The process can further include isolating the adipocytes from remaining hMSCs.

Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.

Abstract: A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. Such compositions have minimized pH-dependent dissolution profiles or pH-independent dissolution profiles.

Abstract: Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semipermeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.

Abstract: A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of suppressor T cells effective to reduce or inhibit host rejection of the transplant. The suppressor T cells can be administered before, at the same time as, or after the transplant. Also disclosed is a method of inducing a reduced immune response against a host by foreign tissue, i.e., graft versus host disease, by treatment with suppressor T cells.

Abstract: The useful life of SOx additives having a SO2→SO3 oxidation catalyst component and a SO3 absorption component can be extended by employing each of these components as separate and distinct physical particles, pellets, etc.

Abstract: The present invention provides immunogenic compositions and methods for inducing enhanced immune responses using an antigen and a combination of water soluble polymer and an amphiphilic compound.

Abstract: Disclosed is a method for recovering peripheral blood containing a population of cells enhanced in human mesenchymal stem cells from an individual by (i) administering to said individual at least one growth factor and, thereafter, (ii) recovering peripheral blood from said individual. The growth factors preferably include G-CSF, GM-CSF and combinations thereof. Any of the known human growth factors or combinations thereof are suitable. Also disclosed is a method for recovering an isolated, culture-expanded population of human mesenchymal stem cells from the mesenchymal stem cell-enriched peripheral blood of an individual. Also disclosed is a method for preserving ex vivo an isolated, culture-expanded population of human mesenchymal stem cells from the mesenchymal stem cell-enriched peripheral blood. Also disclosed is a method for treating an individual with an isolated, culture-expanded population of human mesenchymal stem cells.

Abstract: The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption.

Abstract: In a method of producing an upholstered article, at least first and second cover portions of an upholstery cover are molded in mutually spatially separated relationship. The cover portions are fitted to a core portion to form the upholstery cover therearound. Defined between the outside surface of the core portion and the inside surface of the upholstery cover is a defined gap into which a coating material is introduced. The coating material on hardening joins the upholstery cover to the core portion.

Abstract: A method for inhibiting the differentiation of CD34+ cells into osteoclasts by treating the cells with a peroxisome proliferator-activated receptor-&ggr; agonist.

Abstract: A porous composite product comprised of a network of fibers is produced by forming an unsintered preformed network of fibers and a gasifiable structure forming agent, followed by gasification of the structure forming agent prior to sintering of the fibers at appropriate junction points. The preferred structure forming agent is a cellulosic material.

Abstract: The present invention is directed to hematopoietic progenitor cells isolated from a tissue specimen, such as marrow cells or peripheral blood, and to the method of co-culturing isolated hematopoietic progenitor cells with human mesenchymal stem cells to induce megakaryocyte differentiation and platelet production. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate blood disorders.

Abstract: Described is a coupling device (52) for a telescopically adjustable object such as head support, wherein the object has a first and a second body (24, 18) and the coupling device (52) is such that the first body (24) is adjustable jointly with the second body (18) along a linear guide (38, 40) between a base position and a first extension position and from the first extension position the second body (18) is only adjustable linearly relative to the first body (24) as far as a maximumm position.

Abstract: A product comprised of a three dimensional network of material is coated with a particulate support. The coating may be applied by an electrophoretic coating procedure to apply a particulate coating on the surface or into the interior portions of such three dimensional network of material. In one embodiment, the particles are a catalyst or a catalyst precursor or a catalyst support to thereby provide a catalyst structure in which catalyst may be supported as a coating in the interior and on the exterior of a three-dimensional network of material having a high void volume. Edge effects may be reduced by control or disruption of field lines during the coating. In addition, larger particles may be electrophoretically coated onto a product by the use of smaller particles which function as a “glue”.